LBA: Lebrikizumab Provides Long-Term Efficacy and Safety in Atopic Dermatitis with a Well-Tolerated Safety Profile
Data presented by Prof. Dr. Diamant Thaçi, at EADV 2024 from the ADjoin long-term extension study show that lebrikizumab (LEB), an IL-13 inhibitor, maintains efficacy and safety over a 3-year period.